title: Comparative efficacy of oral rifampin and topical chloramphenicol in eradicating conjunctival carriage of Haemophilus influenzae biogroup aegyptius. Brazilian Purpuric Fever Study Group.
abstract: Persistent conjunctival carriage of the Haemophilus influenzae biogroup aegyptius (Hae) strain (BPF clone) responsible for Brazilian purpuric fever (BPF) has been documented. Topical chloramphenicol is routinely used to treat conjunctivitis in areas affected by BPF in Brazil. Although the BPF clone is susceptible to chloramphenicol, we observed a number of children treated with topical chloramphenicol for conjunctivitis who still developed BPF. During an investigation of an outbreak of BPF in Mato Grosso State, Brazil, we compared oral rifampin (20 mg/kg/day for 4 days) with topical chloramphenicol for eradication of conjunctival carriage of H. influenzae biogroup aegyptius among children with presumed BPF clone conjunctivitis. Conjunctival samples were taken for culture on the day treatment was initiated and a mean of 8 and 21 days later. At 8 days the eradication rates for oral rifampin and topical chloramphenicol were 100 and 44%, respectively (P = 0.003); at 21 days they were 100 and 50% (P = 0.01). Oral rifampin was more effective than topical chloramphenicol for eradication of the BPF clone and may be useful in prevention of BPF.
authors.affiliation: Meningitis and Special Pathogens Branch, National Center for Infectious Diseases, Centers for Disease Control, Atlanta, GA 30333.
authors.forename: B A
authors.initials: BA
authors.lastname: Perkins
authors.forename: M L
authors.initials: ML
authors.lastname: Tondella
authors.forename: I M
authors.initials: IM
authors.lastname: Bortolotto
authors.forename: O A
authors.initials: OA
authors.lastname: Takano
authors.forename: G A
authors.initials: GA
authors.lastname: da Silva
authors.forename: K
authors.initials: K
authors.lastname: Irino
authors.forename: M C
authors.initials: MC
authors.lastname: Brandileone
authors.forename: L H
authors.initials: LH
authors.lastname: Harrison
authors.forename: J D
authors.initials: JD
authors.lastname: Wenger
authors.forename: C V
authors.initials: CV
authors.lastname: Broome
mesh_terms: D000284:Administration, Oral; D000287:Administration, Topical; D001938:Brazil; D002353:Carrier State; D002648:Child; D002675:Child, Preschool; D002701:Chloramphenicol / Q000008:administration & dosage / Q000627:therapeutic use*; D003231:Conjunctivitis / Q000382:microbiology* / Q000517:prevention & control; D005260:Female; D006192:Haemophilus Infections / Q000382:microbiology / Q000517:prevention & control*; D006193:Haemophilus influenzae; D006801:Humans; D007223:Infant; D008297:Male; D009960:Oropharynx / Q000382:microbiology; D011693:Purpura / Q000382:microbiology / Q000517:prevention & control; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use*; D013045:Species Specificity
chemical_list: D002701:Chloramphenicol; D012293:Rifampin